CN121695155A - 减少与甲状腺相关的副作用的方法 - Google Patents

减少与甲状腺相关的副作用的方法

Info

Publication number
CN121695155A
CN121695155A CN202511838413.1A CN202511838413A CN121695155A CN 121695155 A CN121695155 A CN 121695155A CN 202511838413 A CN202511838413 A CN 202511838413A CN 121695155 A CN121695155 A CN 121695155A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
days
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202511838413.1A
Other languages
English (en)
Chinese (zh)
Inventor
布瑞恩·丽安
赫罗科·马萨默纳
马克·埃里翁
布鲁斯·伊藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Original Assignee
Metabasis Therapeutics Inc
Viking Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc, Viking Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of CN121695155A publication Critical patent/CN121695155A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202511838413.1A 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法 Pending CN121695155A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662396025P 2016-09-16 2016-09-16
US201662396015P 2016-09-16 2016-09-16
US62/396,015 2016-09-16
US62/396,025 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects
CN201780068418.8A CN109922812A (zh) 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780068418.8A Division CN109922812A (zh) 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法

Publications (1)

Publication Number Publication Date
CN121695155A true CN121695155A (zh) 2026-03-20

Family

ID=61619247

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202511838413.1A Pending CN121695155A (zh) 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法
CN201780068418.8A Pending CN109922812A (zh) 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780068418.8A Pending CN109922812A (zh) 2016-09-16 2017-09-13 减少与甲状腺相关的副作用的方法

Country Status (9)

Country Link
US (1) US20190255080A1 (https=)
EP (1) EP3512523A4 (https=)
JP (2) JP2019531346A (https=)
KR (2) KR20190060786A (https=)
CN (2) CN121695155A (https=)
AU (1) AU2017327383B2 (https=)
CA (1) CA3037146A1 (https=)
MX (2) MX2019003032A (https=)
WO (1) WO2018053036A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006128058A2 (en) 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11707472B2 (en) 2017-06-05 2023-07-25 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
WO2020225736A1 (en) * 2019-05-08 2020-11-12 Novartis Ag Anti-cd40 antibodies for use in treatment of t1dm and insulitis
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
AU2020334943A1 (en) 2019-08-19 2022-03-10 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
JP7670687B2 (ja) * 2020-02-24 2025-04-30 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
EP1525219B1 (en) * 2002-07-04 2009-05-27 Zealand Pharma A/S Glp-1 and methods for treating diabetes
WO2006128058A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
JP6013736B2 (ja) * 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
US20170319604A1 (en) * 2016-04-22 2017-11-09 Metabasis Therapeutics, Inc. Thyroid hormone receptor agonist and use thereof
CA3044059A1 (en) * 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease

Also Published As

Publication number Publication date
KR20190060786A (ko) 2019-06-03
JP2019531346A (ja) 2019-10-31
MX2023000887A (es) 2023-02-22
JP2022174261A (ja) 2022-11-22
NZ751857A (en) 2024-05-31
CN109922812A (zh) 2019-06-21
MX2019003032A (es) 2019-09-13
JP7656574B2 (ja) 2025-04-03
CA3037146A1 (en) 2018-03-22
WO2018053036A1 (en) 2018-03-22
EP3512523A1 (en) 2019-07-24
AU2017327383A1 (en) 2019-04-11
AU2017327383B2 (en) 2023-06-29
EP3512523A4 (en) 2020-05-06
BR112019005039A2 (pt) 2019-06-25
KR20240074912A (ko) 2024-05-28
US20190255080A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
JP7656574B2 (ja) 甲状腺関連副作用を低下させる方法
JP2025028061A (ja) 肝障害の処置のための組成物及び方法
JP2016185957A (ja) 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター
KR20190104524A (ko) 당원축적질환의 치료 방법
KR20140087037A (ko) 키나제 저해제의 부작용 저감제
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
JP5680412B2 (ja) レオヌリンの使用およびその組成物
EP3730134B1 (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
JP7695246B2 (ja) アルツハイマー病の治療のための化合物
CN109310669B (zh) 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途
JP2018090589A (ja) 肝機能改善法
JPH06279397A (ja) アミノ酸系末梢神経障害改善剤
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
RU2850978C1 (ru) Применение агониста рецептора сфингозин-1-фосфата
WO2013083025A1 (zh) 一种用于制备抗脑血管疾病药物的组合物
US12502371B2 (en) Drug for treating and preventing dementia
JP6875747B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
JP2023545367A (ja) バソプレシン受容体拮抗薬療法の副作用を管理する方法
WO2008038712A1 (fr) Agent thérapeutique/prophylactique du syndrome métabolique
HK40031634A (en) Medicinal composition for preventing or treating secondary hyperparathyroidism under maintenance dialysis
JP2000290198A (ja) 鼻腔抵抗上昇等の抑制剤
EA044268B1 (ru) Способ лечения неалкогольной жировой болезни печени
JPWO2018034351A1 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination